---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-040655"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:49:12.948100+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Kintara and TuHURA enter definitive merger; combined company to focus on immuno-oncology

## Summary
- TuHURA stockholders to own ~97.15% of combined company; Kintara stockholders ~2.85% (or 94.55%/5.45% after CVR shares).
- Combined company to trade as 'HURA' on Nasdaq; merger expected to close in Q3 2024.
- TuHURA plans Phase 3 trial for IFx-2.0 personalized cancer vaccine in 2H 2024 under FDA accelerated approval pathway.
- TuHURA has $31M subscribed financing of convertible notes to provide cash runway into late 2025.
- CVRs issued to Kintara stockholders; up to 53.9M shares if milestone on REM-001 study met by Dec 31, 2025.

## SEC filing metadata
- accession: 0000950170-24-040655
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/0000950170-24-040655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/ktra-20240402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-040655
- JSON: https://secwatch.observer/filing/0000950170-24-040655.json
- Plain text: https://secwatch.observer/filing/0000950170-24-040655.txt

## Key facts
- Material Agreements
  TuHURA Biosciences, Inc./NV entered into Agreement and Plan of Merger with Kintara Therapeutics, Inc., Kayak Mergeco, Inc. (effective 2024-04-02).
  - Action: entry
  - Agreement: merger
  - Counterparty: Kintara Therapeutics, Inc., Kayak Mergeco, Inc.
  - Effective: 2024-04-02
  source text: On April 2, 2024, Kintara Therapeutics, Inc. (“ Kintara ”), Kayak Mergeco, Inc., a wholly-owned subsidiary of Kintara incorporated in the State of Delaware (“ Merger Sub ”), and TuHURA Biosciences, Inc., a Delaware corporation (“ TuHURA ”), entered into an Agreement and Plan of Merger
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/0000950170-24-040655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.